Other skin disorders
Even mild skin disease can cause significant distress for patients, due to associated visibility and stigma, and this is of particular relevance for conditions which affect
...
Latest news articles
Added 19 days ago Drug news
FDA accepts BLA for collagenase clostridium histolyticum to treat patients with cellulite.- Endo International
Endo International plc announced that the FDA has accepted for review the original Biologics License Application (BLA) for collagenase clostridium...
Added 1 month ago Drug news
Cassiopea announces FDA acceptance of its NDA for clascoterone cream 1%, the first new mechanism of action for acne in nearly 40 years.
Cassiopea SpA announced the FDA has accepted for review the New Drug Application (NDA) for clascoterone cream 1%. Cassiopea is...
Added 1 month ago Drug news
Studies FX2014-04 and FX2014-05 of Amzeeq for acne published in Journal of Clinical and Aesthetic Dermatology.- Foamix Pharma
Foamix Pharmaceuticals announced the peer review publication of the long term open label safety portions of studies FX2014-04 and FX2014-05...
Learning Zones
An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.
Idiopathic Pulmonary Fibrosis
Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive fibrotic interstitial lung disease that occurs mostly in older adults, is limited to the lungs and often displays a characteristic imaging and histological appearance. Find out how to diagnose IPF and the latest interventions available for patients living with this burden.
Atopic Dermatitis
The Atopic Dermatitis Knowledge Centre is an educational resource, intended for healthcare professionals, that provides credible medical information on the epidemiology, pathophysiology and burden of atopic dermatitis, as well as diagnostic techniques, treatment regimens and guideline recommendations.
Psoriasis Academy
Learn about the burden of psoriasis, unmet needs, the tools used to assess severity and treatment response, what we know about the pathophysiology behind the condition and what the current guidelines say.
+ 1 more
Chronic Spontaneous Urticaria (CSU)
Use our patient case studies to discover how experts diagnose and treat chronic spontaneous urticaria.
+ 7 more
EADV 2018 Highlights
EADV Congress 2018: Bringing you the latest news and insights from 27th EADV Congress, 12-16 September 2018 Paris, France.
Chronic Lymphocytic Leukaemia (CLL)
Refine your knowledge of chronic lymphocytic leukaemia (CLL) with information on pathophysiology, diagnosis, treatment options and more
+ 1 more
Guidelines
British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017
The overall aim of the guideline is to provide evidence-based recommendations on the use of biologic therapies (adalimumab, etanercept, infliximab, ixekizumab, secukinumab and ustekinumab) in adults, children and young people...
Added 10 years ago
British Association of Dermatologists’ guidelines for the care of patients with actinic keratosis 2017
The overall objective of the guideline is to provide up-to-date, evidence-based recommendations for the management of actinic keratosis (AK).
Added 1 year ago
Canadian Guidelines for the Management of Plaque Psoriasis 2009
Since the publication of the 2009 Canadian Guidelines for the Management of Plaque Psoriasis, significant advances have been made in determining the role of T cells in inflammatory and autoimmune diseases.
Added 2 years ago
Journal articles
A novel nicastrin mutation in a three generation Dutch family with hidradenitis suppurativa
Hidradenitis suppurativa (HS) compromises a multifactorial pathogenesis with a largely unclear aetiology.
Added 2 years ago
Population Pharmacokinetics and Immunogenicity of Adalimumab in Adult Patients with Moderate-to-Severe Hidradenitis Suppurativa
Introduction: Hidradenitis suppurativa (HS) is a serious, debilitating, chronic inflammatory skin disease. Adalimumab is a fully human, immunoglobulin G1 monoclonal antibody specific for tumor necrosis factor-alpha...
Added 2 years ago
NICE approval of adalimumab for moderate-to-severe hidradenitis suppurativa: the end of the beginning for hidradenitis suppurativa therapeutics?
NICE approval of adalimumab for moderate-to-severe hidradenitis suppurativa
Added 2 years ago
Clinical trials
Post-Marketing Surveillance of Adalimumab in Korean Hidradenitis Suppurativa Subjects (HS rPMS)
The objective of this study is to evaluate the safety profile of Adalimumab for Hidradenitis Suppurativa (HS) participants in normal medical practice.
Added 2 years ago
Effectiveness of Adalimumab in Moderate to Severe HidrAdenitis SuppuRativa Patients - a Multi cOuNtry studY in Real Life Setting - HARMONY Study
This study will assess the effects of adalimumab treatment in moderate to severe Hidradenitis Suppurativa (HS) patients in the real world setting.
Added 2 years ago
Safety and Efficacy of Humira (Adalimumab) for Hidradenitis Suppurativa (HS) Peri-Surgically (SHARPS Study) (SHARPS)
The objective of this study is to assess the safety and efficacy of adalimumab prior to surgery in subjects with moderate to severe Hidradenitis Suppurativa (HS) who are surgical candidates.
Added 2 years ago
Lauren McCracken
Lauren McCracken works for our sister agency Digital Medical Communications (DMC Ltd) as an Associate Medical Writer. Lauren is very passionate about healthcare and how technology can improve treatments, and has written a blog series 'Transforming lives through technology'
... Read moreEAACI hot topics: Hereditary angioedema (HAE)
For many the fear of the unknown is a daunting thought, but particularly so for patients with HAE. Left untreated, this disease causes unpredictable recurrent severe swelling, typically of the limbs, face, intestinal tract and airway.
CME
EAACI 2017: The future of urticaria – advances in CSU research
- Accrediting body
-
Union of European Medical Specialists (via European Accreditation Council for CME)
- Credits available
- 1
- Registration required
- 1
- Subscription fee
- FREE
Managing CSU and its comorbidities: from primary to secondary care
- Accrediting body
-
Union of European Medical Specialists (via European Accreditation Council for CME)
- Credits available
- 1
- Registration required
- 1
- Subscription fee
- FREE
Management of hidradenitis suppurativa
- Accrediting body
-
BMJ Learning - British Medical Learning
- Credits available
- 1
- Registration required
- 1
- Subscription fee
- 90